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group, IFA revealed no dye leakage from the
early to late phases (ﬁgure 1AeC).
COMMENT
Our results indicate that eyes with endo-
thelial decompensation after ALI may actu-
ally have a chronic postsurgical breakdown
of the blood-aqueous barrier. Presumably, the
predisposition to postoperative inﬂamma-
tory reactions in patients with ALI-BK
appears to be caused by the manifested
impairment of the blood-aqueous barrier.
Although the reason why such a subclinical
change may continue for a long period of
time after ALI is unclear, the post-ALI
endothelial decompensation may possibly be
due to the humoral transport of substances
such as prostaglandins and cytokines (eg,
TGF-b1) in the anterior segment.
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Changing the status quo bias
We read with interest the article by Durnian
and Clark who presented a retrospective
cohort of infants that fell outside evidence
level B guidelines for screening retinopathy
of prematurity (ROP) and we wish to
discuss some further points.1 The data
presented in table 1 highlight that all 11
babies would be missed if screening was
according to level B evidence and 2 of these
would still be missed using the good practice
points evidence. An alternative conclusion
would be that if the guidelines had been
amended to screen infants under 32 weeks or
1251 g then one extra baby would have been
missed (who fortunately did not require
treatment). It is also debatable based on the
information presented, if any of the babies
absolutely required treatment as others may
have opted to observe the ﬁbrovascular ridge
seen in zone 3 in cases 3 and 12. The
screening criteria should allow the test to be
not only highly sensitive but also speciﬁc. In
order to present a complete discussion, we
would ideally like to know over the same
time period how many examinations would
have been avoided if the screening criteria
were at the secondary level (B) and also
importantly if the criteria were amended to
less than 32 weeks or 1251 g.
The article also stimulates thought as to
what currently deﬁnes the population at risk
of developing ROP. We have moved from
seeing more mature babies with ROP with
higher average birth weights to current
times where the survival of very premature
infants is higher and consequently ROP is
seen in a population that has extremely low
birth weights, at least in highly developed
countries. The inclusion of the Danish cohort
from 1982 to 1987 in the Royal College
Guidelines on ROP 2008 was offered in part
as evidence for the current criteria, but these
data may now be outdated.2 More recent
studies including monitoring of postnatal
weight gain and insulin-like growth factor 1
have had signiﬁcant success in detecting ROP
and offer a potentially safe way to identify
a smaller ‘at risk’ population for screening.3
Ethnicity also has an inﬂuence on the prev-
alence of ROP that may be related to average
birth weight or due to the genetic poly-
morphisms seen in that ethnic group, for this
reason it would be interesting to know the
ethnicity of the infants presented in table 1.4
Anecdotally, over the past 15 years in Brad-
ford where the population is predominantly
Asian, no babies have been treated for ROP
who have weighed more than 1001 g.
Although the genetic susceptibility to
ROP for the majority of cases still remains
elusive, three of the four known genes
implicated in familial exudative vitreoretin-
opathy (FEVR), NDP, FZD4 and LRP5 have
polymorphisms that account for 10e12% of
ROP.5 For cases that fall outside the
currently accepted ‘at risk’ guidelines (eg.
case 10), it may be worth contemplating if in
fact they have a clinically identical condi-
tion, FEVR, or at least a genetic basis for an
increased susceptibility to develop abnormal
retinal vasculature when exposed to envi-
ronmental stressors (that may be tested for
in future screening algorithms). For this
reason, it may also be important to know
the systemic clinical condition of the
neonates presented during their inpatient
stay.
Using our current guidelines, we are only
treating approximately 10% of cases
screened; even if this strategy allowed us to
identify all cases, this would be enough
reason to suggest a reﬁnement of the current
criteria. We feel that as our understanding of
molecular genetics evolves, advances in
neonatal care continues to improve together
with changes in the UK population demo-
graphic re-examination of the screening
criteria will become necessary.
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keratoplasty: a therapeutic option
for severe corneal ulcerations
and melting disorders
In cases of severe corneal melting, immediate
penetrating keratoplasty (PK) can be
required but is accompanied by a high prev-
alence of complications due to ongoing
inﬂammatory stimuli and wound-healing
disorders. In these situations, the properties
of amniotic membrane (AM) including
promotion of epithelial healing as well as
antiangiogenic, anti-infectious, antiscarring
and immunemodulatory effects can be
beneﬁcial. In the context of PK and AM
transplantation (AMT) different surgical
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approaches are possible: (1) AMT prior to
PK; (2) PK with simultaneously performed
AM patch, as described in this study; and (3)
AMT after PK. Potential advantages of
a simultaneous AMT with PK may include
the following. First, epitheliotrophic effects
of the AM promote wound healing and
epithelialisation of the graft and therefore
allow early topical steroid application.1
Second, immune-modulatory effects of the
AM on the ocular surface in the early phase
after PK may reduce the risk of immuno-
logical graft rejection. AM provides a barrier
between immune-competent cells in the tear
ﬁlm and the corneal graft, and may attract
and trap inﬂammatory cells.2 AM itself
seems to be an immune-privileged tissue, and
this property might be transfered to the
grafted corneal tissue.3 4 Third, prevention of
early neovascularisation of the corneal graft
by the antiangiogenic effect of AM not only
sustains graft clarity, but also reduces the
risk of immune rejection.5 6
The purpose of this study was to evaluate
the combination of emergency PK with
simultaneous AMT in severe corneal melting
disorders to analyse the impact on the short
and intermediate-term postoperative perfor-
mance of the graft in terms of epithelial
wound healing and graft survival in
comparison with PK without AMT.
We performed a retrospective, non-rando-
mised, single-centre observational case series.
Clinical ﬁles from 53 patients with corneal
melting disorders related to different infec-
tious and non-infectious diseases who
underwent emergency PK because of corneal
perforation or predescemetal ulceration were
analysed. PK was performed either with
simultaneous AMT in 20 patients (group 1)
or without AMT in 33 patients (group 2); the
median age at the time of PKwas 73/63 years.
We used cryopreserved AMs exclusively.
The follow-up time was 7.8/9.5 months on
average. The main outcome measures
included postoperative rate of persistent
epithelial defects, graft clarity and subse-
quent surgical procedures.
In group 1, the AM was lost after
8.663 days on average. After this time, the
epithelium was closed in 85% of the eyes.
Eyes of group 1 showed less persistent
postoperative epithelial defects: in 90% of
eyes in group 1 versus 61% of eyes in group
2, the corneal epithelium was closed within
4 weeks (p¼0.02; c2 test; ﬁgure 1). Only 20%
of eyes in group 1 developed new corneal
epithelial defects or corneal ulcers versus
42% in group 2, but this effect was statisti-
cally not signiﬁcant (NS). Thirty per cent in
group 1 and 46% in group 2 showed suture
loosening; approximately one-third of
patients in both groups (35% in group 1 vs
36% in group 2) required subsequent surgical
procedures during the follow-up period. At
the end of follow-up, most of the grafts (80%
in group 1, 70% in group 2, NS) were clear
without scarring or corneal oedema.
CONCLUSION
Simultaneous AMT as a patch can be bene-
ﬁcial in eyes with severe corneal melting
disorders requiring immediate PK by
promoting postoperative wound healing and
by subsequently increasing the prognosis of
the corneal graft. This technique offers an
alternative strategy in advanced cases of
corneal melting.
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Figure 1 (A) Deep herpetic corneal ulcer with predescemetal ulceration after ipsilateral eccentric autologous rotational penetrating keratoplasty (PK),
cataracta provecta. (B) First day after eccentric elliptical excimer laser PK (7.038.0/7.138.1 mm) with simultaneous extracapsular cataract
extraction, posterior chamber intraocular lens implantation and 14.0 mm amniotic membrane patch. (C) Clear graft with complete epithelial closure
4 weeks after PK and 2 weeks after spontaneous detachment of the amniotic membrane patch.
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